Liraglutide yog ib qho GLP-1 analog nrog 97% ua raws li homology rau tib neeg GLP-1. Tib neeg GLP-1 tuaj yeem khi rau thiab qhib GLP-1 receptor. GLP-1 receptor yog lub hom phiaj ntawm ntuj GLP-1. GLP-1 yog ib qho tshuaj endogenous incretin uas tuaj yeem txhawb nqa cov piam thaj hauv cov ntshav los ntawm kev tso tawm ntawm insulin los ntawm pancreatic beta hlwb. Sib txawv ntawm ntuj GLP-1, cov tshuaj pharmacokinetic thiab pharmacodynamic yam ntxwv ntawm liraglutide hauv tib neeg yog tsim nyog rau kev noj tshuaj ib zaug ib hnub. Tom qab txhaj tshuaj subcutaneous, cov txheej txheem ntawm lub sijhawm ua haujlwm ntev suav nrog: kev sib koom ua ke ntawm tus kheej uas ua rau kom nqus tau sai; khi rau albumin; Ntau dua enzyme stability, uas muaj lub plasma ntev ib nrab-lub neej.
Cov kev ua ntawm liraglutide yog kho los ntawm nws cov kev cuam tshuam tshwj xeeb nrog GLP-1 receptor, uas ua rau muaj kev nce hauv cyclic adenosine monophosphate (cAMP). Liraglutide tuaj yeem tsim cov tshuaj insulin secretion hauv hom ntshav qab zib hom 2, thiab tib lub sijhawm txo qis pancreas ntau dhau hauv hom ntshav qab zib hom 2.
secretion ntawm cov piam thaj ntau. Yog li ntawd, thaum cov ntshav qab zib nce siab, insulin secretion yog stimulated, thaum glucagon secretion yog inhibited. Hauv qhov sib piv, liraglutide tuaj yeem txo qis cov tshuaj insulin thaum lub sijhawm hypoglycemia yam tsis muaj kev cuam tshuam rau kev tso tawm ntawm glucagon. Liraglutide' cov txheej txheem hypoglycemic kuj suav nrog kev ncua ntev ntawm lub plab zom mov. Liraglutide tuaj yeem txo lub cev hnyav thiab lub cev rog los ntawm kev txo qis kev tshaib kev nqhis thiab lub zog noj.

